NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 58.00

+3.6%

Nov 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: idos who wrote (355)	3/16/2011 1:21:48 PM
From: ghmm	Read Replies (1) of 507

Yes I believe all the additional patients will have had Doxil. I didn't recall hearing the company say if it would be q14d or q21d. I took it for granted it would be q21d based on a bit lower toxicity especially after hearing the doc in the Breast Cancer presentation suggest that dosing may be better in that indication.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next